<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H96E8E45A81B54FD6A39F2FD81DB37509" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 427 IH: Support And Value Expectant Moms and Babies Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-01-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 427</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20230120">January 20, 2023</action-date>
<action-desc><sponsor name-id="L000566">Mr. Latta</sponsor> (for himself, <cosponsor name-id="H001086">Mrs. Harshbarger</cosponsor>, <cosponsor name-id="A000055">Mr. Aderholt</cosponsor>, <cosponsor name-id="R000610">Mr. Reschenthaler</cosponsor>, <cosponsor name-id="L000595">Ms. Letlow</cosponsor>, <cosponsor name-id="F000475">Mr. Finstad</cosponsor>, <cosponsor name-id="G000576">Mr. Grothman</cosponsor>, <cosponsor name-id="L000569">Mr. Luetkemeyer</cosponsor>, <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>, <cosponsor name-id="B001295">Mr. Bost</cosponsor>, <cosponsor name-id="B001291">Mr. Babin</cosponsor>, <cosponsor name-id="P000609">Mr. Palmer</cosponsor>, <cosponsor name-id="W000815">Mr. Wenstrup</cosponsor>, <cosponsor name-id="E000071">Mr. Ellzey</cosponsor>, <cosponsor name-id="M001211">Mrs. Miller of Illinois</cosponsor>, <cosponsor name-id="S000522">Mr. Smith of New Jersey</cosponsor>, <cosponsor name-id="B001299">Mr. Banks</cosponsor>, <cosponsor name-id="F000446">Mr. Feenstra</cosponsor>, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="B001302">Mr. Biggs</cosponsor>, <cosponsor name-id="F000472">Mr. C. Scott Franklin of Florida</cosponsor>, <cosponsor name-id="W000814">Mr. Weber of Texas</cosponsor>, <cosponsor name-id="W000798">Mr. Walberg</cosponsor>, <cosponsor name-id="L000585">Mr. LaHood</cosponsor>, <cosponsor name-id="J000304">Mr. Jackson of Texas</cosponsor>, <cosponsor name-id="M000871">Mr. Mann</cosponsor>, <cosponsor name-id="B001306">Mr. Balderson</cosponsor>, <cosponsor name-id="R000612">Mr. Rose</cosponsor>, <cosponsor name-id="G000591">Mr. Guest</cosponsor>, <cosponsor name-id="B000825">Mrs. Boebert</cosponsor>, <cosponsor name-id="W000823">Mr. Waltz</cosponsor>, <cosponsor name-id="P000605">Mr. Perry</cosponsor>, and <cosponsor name-id="M001156">Mr. McHenry</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the approval of new abortion drugs, to prohibit investigational use exemptions for abortion drugs, and to impose additional regulatory requirements with respect to previously approved abortion drugs, and for other purposes.</official-title>
</form>
<legis-body id="H2A9A195D0CD249ECBC266416F3388624" style="OLC"> 
<section id="H8C8CFA9A84974CC98B01611F31E13E9F" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Support And Value Expectant Moms and Babies Act of 2023</short-title></quote> or the <quote><short-title>SAVE Moms and Babies Act of 2023</short-title></quote>.</text></section> <section id="HAE947069C5744F3EAAC212FE514AE2FB"><enum>2.</enum><header>Abortion drugs prohibited</header> <subsection id="H1143D18FC6154920811E28BEDFFC9D26"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) (as amended by <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="HEAEE38BC05B8483FA39160FC8DB9FA27" style="OLC"> 
<subsection id="HBD0D850DEFEF4071B7D3142726EC3F99"><enum>(aa)</enum><header>Abortion drugs</header> 
<paragraph id="HD42E39A21FED45B7999C68A312CFC062"><enum>(1)</enum><header>Prohibitions</header><text display-inline="yes-display-inline">The Secretary shall not approve—</text> <subparagraph id="H0C659ADB928F47D9AFBC878AD5CBA9F8"><enum>(A)</enum><text>any application submitted under subsection (b) or (j) for marketing an abortion drug; or</text></subparagraph> 
<subparagraph id="H14947611A18E446C95447FC8AE8EE4AC"><enum>(B)</enum><text>grant an investigational use exemption under subsection (i) for—</text> <clause id="H362A4897A7334BB0BC4C55F5A0756EC4"><enum>(i)</enum><text>an abortion drug; or</text></clause> 
<clause id="H3DE028A6925D47EA8326707194991CE9"><enum>(ii)</enum><text display-inline="yes-display-inline">any investigation in which the unborn child of a woman known to be pregnant is knowingly destroyed.</text></clause></subparagraph></paragraph> <paragraph id="HDB38EB68A02D44F59226F9A1E293F699"><enum>(2)</enum><header>Previously approved abortion drugs</header><text display-inline="yes-display-inline">If an approval described in paragraph (1) is in effect for an abortion drug as of the date of enactment of the <short-title>Support And Value Expectant Moms and Babies Act of 2023</short-title>, the Secretary shall—</text> 
<subparagraph id="HC609A1A6374E4F76A81F2B249C76C77D"><enum>(A)</enum><text>not approve any labeling change—</text> <clause id="HFF4811E741114A80B3FD5C68FA747CA8"><enum>(i)</enum><text>to approve the use of such abortion drug after 70 days gestation; or</text></clause> 
<clause id="HE0D51AEF38284DCDAA7D0B2880116F50"><enum>(ii)</enum><text>to approve the dispensing of such abortion drug by any means other than in-person administration by the prescribing health care practitioner;</text></clause></subparagraph> <subparagraph id="H4EC994EB3DEF42EF999ADC0509DB0280"><enum>(B)</enum><text>treat such abortion drug as subject to section 503(b)(1); and</text></subparagraph> 
<subparagraph id="HD0EF40C08BC943CC9AC7149150A65B11"><enum>(C)</enum><text>require such abortion drug to be subject to a risk evaluation and mitigation strategy under section 505–1 that at a minimum—</text> <clause id="H6EC71825342E4DDF9CADF6B3ADDE265C"><enum>(i)</enum><text display-inline="yes-display-inline">requires health care practitioners who prescribe such abortion drug—</text> 
<subclause id="H20C8346444C246828E4E4FFF68F4CE6F"><enum>(I)</enum><text>to be certified in accordance with the strategy; and</text></subclause> <subclause id="HCD9D8A727F50487D93380FDD30512B75"><enum>(II)</enum><text>to not be acting in their capacity as a pharmacist;</text></subclause></clause> 
<clause id="H81E63F48B485415E998203F2D86C39B2"><enum>(ii)</enum><text display-inline="yes-display-inline">as part of the certification process referred to in clause (i), requires such practitioners—</text> <subclause id="HF02C65EDBDA04278B13AA7DB52B89474"><enum>(I)</enum><text>to have the ability to assess the duration of pregnancy accurately;</text></subclause> 
<subclause id="H9E5561C18A5F463DB677F8709D322316"><enum>(II)</enum><text>to have the ability to diagnose ectopic pregnancies;</text></subclause> <subclause id="HDEC93FC071104FD7B82D792C08935BA9"><enum>(III)</enum><text>to have the ability to provide surgical intervention in cases of incomplete abortion or severe bleeding;</text></subclause> 
<subclause id="H158B43B68FBD42F09756094E58C4780A"><enum>(IV)</enum><text>to have the ability to ensure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary; and</text></subclause> <subclause id="H200E1B02A037486A9B1EF59EEF824FD9"><enum>(V)</enum><text>to report any deaths or other adverse events associated with the use of such abortion drug to the Food and Drug Administration and to the manufacturer of such abortion drug, identifying the patient by a non-identifiable reference and the serial number from each package of such abortion drug;</text></subclause></clause> 
<clause id="HEFD88B2FFD85405CBA916CA77109E2DB"><enum>(iii)</enum><text>limits the dispensing of such abortion drug to patients—</text> <subclause id="H18EBFC76A10B480382AC8DD7843B5240"><enum>(I)</enum><text display-inline="yes-display-inline">in a clinic, medical office, or hospital by means of in-person administration by the prescribing health care practitioner; and</text></subclause> 
<subclause id="HCEB77F51789B4F468C5665E94A0ED3C2"><enum>(II)</enum><text>not in pharmacies or any setting other than the health care settings described in subclause (I);</text></subclause></clause> <clause id="H89457B7F1FF94DF2BC997ED03A8A69F7"><enum>(iv)</enum><text>requires the prescribing health care practitioner to give to the patient documentation on any risk of serious complications associated with use of such abortion drug and receive acknowledgment of such receipt from the patient;</text></clause> 
<clause id="H909B7DACA24E45899E2B02B76E52E817"><enum>(v)</enum><text>requires all known adverse events associated with such abortion drug to be reported, excluding any individually identifiable patient information, to the Food and Drug Administration by the—</text> <subclause id="HC0804910D3514655ACA96389532D52AF"><enum>(I)</enum><text>manufacturers of such abortion drug; and</text></subclause> 
<subclause id="H1DABDD70E11D4EFB84BB228C644FCEC5"><enum>(II)</enum><text>prescribers of such abortion drug; and</text></subclause></clause> <clause id="H9B499FF496534639B7E27E9A34B02157"><enum>(vi)</enum><text display-inline="yes-display-inline">requires reporting of administration of the abortion drug as required by State law, or in the absence of a State law regarding such reporting, in the same manner as a surgical abortion.</text></clause></subparagraph></paragraph> 
<paragraph id="HDC5BCCD2CAC346208B53839B7F4D518E"><enum>(3)</enum><header>Reporting on adverse events by other health care practitioners</header><text display-inline="yes-display-inline">The Secretary shall require all other health care practitioners to report to the Food and Drug Administration any adverse events experienced by their patients that are connected to use of an abortion drug, excluding any individually identifiable patient information.</text></paragraph> <paragraph id="H5D89F505B02F47E0B15F6B99E3E15599"><enum>(4)</enum><header>Rule of construction</header><text>Nothing in this section shall be construed to restrict the authority of the Federal Government, or of a State, to establish, implement, and enforce requirements and restrictions with respect to abortion drugs under provisions of law other than this section that are in addition to the requirements and restrictions under this section.</text></paragraph> 
<paragraph id="HC818C0EF626B411DABBC2A27C8BF1498"><enum>(5)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text> <subparagraph id="H2349811146C64A18A1D2F971CF22E022"><enum>(A)</enum><text display-inline="yes-display-inline">The term <term>abortion drug</term> means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than—</text> 
<clause id="H8D370AD2AAFE44B9A12F62A4B5F77E3C"><enum>(i)</enum><text>to produce a live birth;</text></clause> <clause id="H7A007CB11C92436699A98289C523AA70"><enum>(ii)</enum><text>to remove a dead unborn child; or</text></clause> 
<clause id="H9EDBAFC8BCE94D369729F9FD03BD0076"><enum>(iii)</enum><text>to treat an ectopic pregnancy.</text></clause></subparagraph> <subparagraph id="HFB9E6CE3880A407A85702105BC8C80AF"><enum>(B)</enum><text>The term <term>adverse event</term> includes each of the following:</text> 
<clause id="H61BA7A4A137E46C6B09ED0F6DA285252"><enum>(i)</enum><text>A fatality.</text></clause> <clause id="HAF8A64E82EDD482A8B124320352A8B63"><enum>(ii)</enum><text>An ectopic pregnancy.</text></clause> 
<clause id="H2B7B93B301E54027AB1861043D2C1B4B"><enum>(iii)</enum><text>A hospitalization.</text></clause> <clause id="H3360E0133E294EF2806A0CE911D0BD9F"><enum>(iv)</enum><text>A blood loss requiring a transfusion.</text></clause> 
<clause id="HC07CB94AA78F4913ACC6A2B8E3695EB5"><enum>(v)</enum><text>An infection, including endometritis, pelvic inflammatory disease, and pelvic infections with sepsis.</text></clause> <clause id="H32A03D58F29C435296A501016A4F1EAB"><enum>(vi)</enum><text>A severe infection.</text></clause></subparagraph> 
<subparagraph id="HF9EF9BEB1A004B0D9C4F69A09EB30651"><enum>(C)</enum><text display-inline="yes-display-inline">The term <term>gestation</term> means the period of days beginning on the first day of the last menstrual period.</text></subparagraph> <subparagraph id="H870865031AFD401E881CA029E076E103"><enum>(D)</enum><text display-inline="yes-display-inline">The term <term>health care practitioner</term> means any individual who is licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which the individual practices, to prescribe drugs subject to section 503(b)(1).</text></subparagraph> 
<subparagraph id="H19FC54FC9A6844809E0B46906E666278"><enum>(E)</enum><text display-inline="yes-display-inline">The term <term>unborn child</term> means an individual organism of the species homo sapiens, beginning at fertilization, until the point of being born alive as defined in section 8(b) of title 1, United States Code.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H09102A9C75254592951149411A3D6CBC"><enum>(b)</enum><header>Ongoing investigational use</header><text display-inline="yes-display-inline">In the case of any investigational use of a drug pursuant to an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) that was granted before the date of enactment of this Act, such exemption is deemed to be rescinded as of the day that is 3 years after the date of enactment of this Act if the Secretary would be prohibited by section 505(aa)(1)(B) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), from granting such exemption as of such day.</text></subsection></section> 
</legis-body>
</bill>


